Infectious Mortality in ARD Infectious conditions are a significant cause of mortality in ARD. Among patients hospitalized with an infection, we compared in-hospital and long-term (3-year) mortality between those with and without ARD. https://t.co/p4n5Los89F https://t.co/vUBLC9TDDG

Save the date! We’ll be covering #EULAR24! https://t.co/HGjP2SFyOp

Small-molecule Drugs to Treat Systemic Lupus Erythematosus A metanalysis of randomized controlled trials (RCTs) on treatments of systemic lupus erythematosus (SLE), confirm the efficacy of several targeted small-molecule drugs. https://t.co/ZYPZcfKrBD https://t.co/ZGYFNVgN0s

A unique study in military medicine of 1.5 million ED visits reveals the dynamics of high-rank and high-power patients and doctors, and the care they get/provide https://t.co/hbsUt1s9YR @ScienceMagazine @sdschwab @vini_singh_ https://t.co/RIjq4awgeR

Interferons and Lupus Subsets In a new study, researchers from Johns Hopkins Medicine say they have uncovered insights as to the relationship between interferons and lupus, which affects up to 1.5 million Americans. https://t.co/eWnNqVUpK9 https://t.co/yNp4GYHYKu

Risk Factors for Hydroxychloroquine Retinopathy A long-term hydroxychloroquine users study found that 2.7% developed retinopathy, and identified risk factors as increasing age, female sex, chronic kidney disease stage 3+ and tamoxifen use. https://t.co/3HWWoCMXfI https://t.co/TuYgzRJEzR

Single center EHR study of 5 064 pts w/ pre-diabetes compared those starting metformin (1154) vs 13 877 non-users w/ ~4 yrs F/U. Incidence of future gout was lower w/ metformin use (7.1 vs 9.5/1000PYs; HR 0.68); with no change in SUA or CRP https://t.co/CXdcEdWXhW https://t.co/j0ktehf9Sm

2023 Top 3 paper from JAMA Derm - 122 plaque psoriasis pts (mild-mod w/ PASI=3.1) & low vit D levels (~14.9), Rx w/ PBO vs vit D 20 000 IU/wk x 4 mos during winter; no signif vit D Rx benefit for PASI, MD global, DLQI or 25-OH levels(< than expected) https://t.co/8W5abvydY6 https://t.co/rKJjkiHwC6

My Cancelled Lecture (5.11.2024) In lieu of this weeks podcast, Dr. Jack Cush records his "Life Lessons (that keep changing) in Rheumatology Lecture. A lecture recently cancelled because some of this content was objectionable? (I dont think so!) https://t.co/8iObw8cE5S https://t.co/k06P4mMwmD

Inflammatory Myositis market size was valued at ~$575 million USD in 2022 with 184,204 confirmed IMM cases in the 7MM. In the USA there were 90,064 cases in 2022 https://t.co/uLtxOYGrLr https://t.co/W5TApBDV3C

Metanalysis of 26 reports and 195 juvenile Dermatomyositis pts (age 4.9 yrs) treated w/ JAK inhib (tofa, rux, & bari); Good improvement in 90%, 69% & 93%, respectively. JAK indication refractory skin dz (35%) or muscle involvement (29%). TIME FOR RCTs!! https://t.co/0aaLV7iCWR https://t.co/DLGRqqmIyX

National French study finds post COVID Vaccine the IR of PMR (179 cases; RR 7.1/mill) & GCA (54 cases; RR 2.1 /million) were reported 7-10d post vax. These #s are below population incidence rates (1-20/mill for GCA) https://t.co/XvaoWhqs2g https://t.co/BFDy2WKcLx